

2020-12-11 dr kailas - 1st patient appt pre appt notes

Please describe your symptoms.

2020-12-10

Jeffrey Thomas Bodin

Lactose Intolerance / Lactose Allergy

- diarrhea
- massive conflicts with medications
- issues for finding new medications
- priority

Stomach Ulcers

- circa 2008 / 2009
- Need to follow-up on these and applicability to furtherance of treatment.

Please list any medications you are currently taking for this condition.

2020-12-10

Jeffrey Thomas Bodin

Lactose Intolerance / Allergy

- Take 3 at meal time pills for this
- Does little to NOTHING to assist with this
- Am unable to consume lactose.
- More importantly,
- Am unable to utilize medication containing lactose.
- priority

Stomach Ulcers

- Previously taken 2008-08-27~
- Carafate 1GM/10ML Suspension
- Previously taken 2008-09-17~
- This treatment "worked"
- However,
- Lactose allergy / intolerance.
- Plus, extremely sensitive stomach, prohibitive in diet.
- Has persisted to this day.
- Remaining an issue.

Please describe any probable cause for these symptoms.

2020-12-10

Jeffrey Thomas Bodin

Lactose Intolerance / Allergy

Stomach Ulcers

REPORT: RX0920

02/08/10

LA WALGREENS PURGED DATA FOR STORE 05382

PAGE: 207325

PAT LAST NAME

FIRST

PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DRUG NAME	DRUG MFR	CTL	PLAN	RX IMAGE ID	DEA#	PLAN
DOC NAME	DOC ADDRESS				DOC PHONE#		
ORIG DATE	QTY	REFILLS	DAYS	SUPPLY	RX COMMENTS		
ENTER DATE	CIND	ENT/VER	FILL	QTY	REFILL	CUST AMT	TOT AMT
AUTH NBR	AUTH BY						
09/06/2008	XXX/LSR	4	RFL003			10.00	0.00
RX 0906560	FLUOXETINE 10MG CAPSULES	SANDOZ					
CASEY, S 71107 HWY 21 COVINGTON, LA 70471-3317							
SIG: G "JEFFREY" ONE C PO QAM							
06/13/2008	30	1		30			
06/17/2008	LSR/LSR	30	ORIG			21.99	0.00
06/13/2008	BJG/JWT	0	ADDRFL				
06/17/2008	LSR/JWT	2					
2	PER						
08/11/2008	SMW/JWT	30	RFL001			10.00	0.95
RX 0925082	KEPPRA 250MG TABLETS	UCB					
DESMOND, S 200 HENRY CLAY AVE KENNER, LA 70471-3317							
SIG: G TWO TS PO QAM AND TWO QPM FOR 7 DAYS, THEN G TWO TS QAM AND THREE TS QPM							
XFER TO STORE: 5382 RX#: 0931212 RPH INIT: JWT ENT INIT: XXX 08/27/2008							
08/08/2008	143	0		30			
08/08/2008	SMW/JWT	24	ORIG			35.00	31.78
08/08/2008	DSB/BJG	119	RFL001			0.00	352.26
RX 0931212	KEPPRA 250MG TABLETS	UCB					
DESMOND, S 200 HENRY CLAY AVE KENNER, LA 70471-3317							
SIG: G TWO TS PO QAM AND TWO QPM FOR 7 DAYS, THEN G TWO TS QAM AND THREE TS QPM							
08/27/2008	143	0		30			
08/27/2008	XXX/JWT	0	ADDRFL				
0							
RX 0931427	CARAFATE 1GM/10ML SUSPENSION	AXCAN					
MORALES, J 200 HENRY CLAY AVE NEW ORLEANS, LA 70471-3317							
SIG: SAS 1 TEA QID							
XFER TO STORE: 5382 RX#: 0936470 RPH INIT: JWT ENT INIT: XXX 09/14/2008							
08/27/2008	200	0		10			
08/27/2008	BJG/BJG	200	ORIG			35.00	0.00
RX 0931429	*MAGIC MOUTHWASH	N					
MORALES, J 200 HENRY CLAY AVE NEW ORLEANS, LA 70471-3317							
SIG: SAS 2 TES QID. SKAKE WELL							
XFER TO STORE: 5382 RX#: 0936471 RPH INIT: JWT ENT INIT: XXX 09/14/2008							
08/27/2008	360	0		9			
08/27/2008	BJG/BJG	360	ORIG			35.00	0.00
RX 0932119	KEPPRA 250MG TABLETS	UCB					
MORALES, J 200 HENRY CLAY AVE NEW ORLEANS, LA 70471-3317							
SIG: G "JEFFREY" 3 TS PO BID							
08/28/2008	180	2		30			
08/28/2008	DSB/JWT	180	ORIG			35.00	451.90
09/27/2008	XXX/BJG	180	RFL001			35.00	476.13
RX 0934786	CHLORHEXIDINE ORAL RINSE 473ML	XTTRIUM					
MORALES, J 200 HENRY CLAY AVE NEW ORLEANS, LA 70471-3317							
SIG: SWISH AND SPIT OUT 10MLS PO TID							
09/09/2008	473	1		16			

REPORT: RX0920

02/08/10

LA WALGREENS PURGED DATA FOR STORE 05382

PAGE: 207326

PAT LAST NAME

FIRST


PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DRUG NAME	DRUG MFR	CTL	PLAN	RX IMAGE ID	DOC PHONE#	DEA#
RX 0936470	CARAFATE 1GM/10ML SUSPENSION	AXCAN	RX	PERX	0538264121987114613	(504)896-9740	BM9735169
MORALES, J 200 HENRY CLAY AVE NEW ORLEANS, LA 70471-3317							
SIG: SAS 1 TEA QID							
09/14/2008	200	2	10				
09/17/2008	GJP/GJP	200					PERX
09/14/2008	XXX/GJP	0					ADDRFL
0							
09/17/2008	GJP/GJP	3					
3	FAX						
RX 0936471	*MAGIC MOUTHWASH	N	RX	PERX	0538264121987114613	(504)896-9740	BM9735169
MORALES, J 200 HENRY CLAY AVE NEW ORLEANS, LA 70471-3317							
SIG: SAS 2 TES QID. SKAKE WELL							
09/14/2008	360	2	9				
09/17/2008	GJP/GJP	360					PERX
09/14/2008	XXX/GJP	0					ADDRFL
0							
09/17/2008	GJP/GJP	3					
3	FAX						
RX 0938884	ONDANSETRON 4MG TABLETS	DR.REDDY'S	RX		0538246122204120713	(504)899-9511	AT3365295
HOSPITAL, C 200 HENRY CLAY AVE NEW ORLEANS, LA 70471-3317							
SIG: G "JEFFREY" ONE T PO Q 8 H PRN NV							
09/21/2008	20	0	3				
09/21/2008	XXX/JWT	0					ADDRFL
0							

COMPOUND SUMMARY


Carafate

PubChem CID:	70789197
Structure:	 Find Similar Structures
Molecular Formula:	C ₁₁ H ₄₄ Al ₈ O ₅₁ S ₈
Synonyms:	Antepsin Carafate Sucralfat Sucramal Sulcrate <input type="button" value="More..."/>
Molecular Weight:	1464.8 g/mol
Dates:	Modify: 2019-11-09 Create: 2013-03-06
<p>Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655]. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].</p> <ul style="list-style-type: none">▶ from DrugBank <p>A basic aluminum complex of sulfated sucrose.</p> <ul style="list-style-type: none">▶ from MeSH	

1 Structures



1.1 2D Structure



▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

1.2 3D Status



Conformer generation is disallowed since too many atoms, MMFF94s unsupported element, MMFF94s unsupported atom valence, too flexible, mixture or salt

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

C₁₁H₄₄Al₈O₅₁S₈

Computed by PubChem 2.1 (PubChem release 2019.06.18)

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

2.3 Other Identifiers



2.3.1 CAS



54182-58-0

▼ from DrugBank

Source: DrugBank

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

2.4 Synonyms



2.4.1 MeSH Entry Terms



Aluminum Sucrose Sulfate
Antepsin
Basic Aluminum Sucrose Sulfate
Carafate
Sucralfate
Sulfate, Aluminum Sucrose
Ulcerban
Ulcogant
Ulsanic

▼ from MeSH

Source: MeSH

Record Name: Sucralfate

URL: <https://www.ncbi.nlm.nih.gov/mesh/68013392>

2.4.2 Depositor-Supplied Synonyms



Antepsin	[[[[(2S,3R,4S,5R,6R)-4,5-bis([[dihydroxyalumanyl]oxy)sulfonyl]oxy)-6-[[[(dihydroxyalumanyl)oxy)sulfonyl]oxy)methyl]-2-[[[(2R,3S,4S,5R,6R)-4,5-bis([[dihydroxyalumanyl]oxy)sulfonyl]oxy)-2-[[[(dihydroxyalumanyl)oxy)sulfonyl]oxy)methyl]oxolan-2-yl]oxy]oxan-3-yl]oxy)sulfonyl]oxy]hexadecaaluminum
Carafate	
Sucralfat	Hexadeca-mu-hydroxytetracosahydroxy[μ 8-[1,3,4,6-tetra-O-sulfo-beta-D-fructofuranosyl-alpha-D-glucopyranoside tetrakis(hydroxy sulfato)8-]]hexadecaaluminum
Sucramal	
Sulcrate	
Ulcermin	
Apo-sucralfate	
Sulcrate Suspension Plus	
GTPL7055	
DB00364	

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

3 Chemical and Physical Properties



3.1 Computed Properties



Property Name	Property Value	Reference
Molecular Weight	1464.8 g/mol	Computed by PubChem 2.1 (PubChem release 2019.06.18)
Hydrogen Bond Donor Count	16	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Hydrogen Bond Acceptor Count	51	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Rotatable Bond Count	36	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Exact Mass	1463.713824 g/mol	Computed by PubChem 2.1 (PubChem release 2019.06.18)
Monoisotopic Mass	1463.713824 g/mol	Computed by PubChem 2.1 (PubChem release 2019.06.18)
Topological Polar Surface Area	532 Å ²	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Heavy Atom Count	78	Computed by PubChem
Formal Charge	0	Computed by PubChem
Complexity	2400	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Isotope Atom Count	0	Computed by PubChem
Defined Atom Stereocenter Count	9	Computed by PubChem
Undefined Atom Stereocenter Count	0	Computed by PubChem
Defined Bond Stereocenter Count	0	Computed by PubChem
Undefined Bond Stereocenter Count	0	Computed by PubChem
Covalently-Bonded Unit Count	17	Computed by PubChem
Compound Is Canonicalized	Yes	Computed by PubChem (release 2019.01.04)

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

3.2 Experimental Properties



3.2.1 Melting Point



>220

<https://www.trc-canada.com/product-detail/?S692350>

▼ from DrugBank

Source: DrugBank

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

3.2.2 Solubility



Insoluble

https://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx

▼ from DrugBank

Source: DrugBank

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

3.2.3 Octanol/Water Partition Coefficient



-7.087

http://www.molbase.com/en/overview_54182-58-0-moldata-62765.html

▼ from DrugBank

Source: DrugBank

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

3.2.4 pKa



0.43 to 1.19

https://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx

▼ from DrugBank

Source: DrugBank

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>






Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

4 Related Records



4.1 Related Compounds with Annotation

37 items [View More Rows & Details](#)

Structure	Compound CID	Name	Molecular Formula	Molecular Weight, g/mol
	444237	Sucrose octasulfate	$C_{12}H_{22}O_{35}S_8$	982.8
	5312151	[[2R,3S,4S,5R]-2,4-Disulfooxy-5-(sulfooxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trisulfooxy-6-(sulfooxymethyl)oxan-2-yl]oxyoxolan-3-yl] hydrogen sulfate	$C_{11}H_{20}O_{35}S_8$	968.8
	6398588	Aluminum;[(2R,3S,4S,5R)-2,4-disulfonatooxy-5-(sulfonatooxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyoxolan-3-yl] sulfate;trihydrate	$C_{11}H_{18}AlO_{38}S_8^{-8}$	1041.8
	11629450	[[2R,3R,4R,5R)-2,5-Bis(sulfooxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trisulfooxy-6-(sulfooxymethyl)oxan-2-yl]oxyoxolan-3-yl] hydrogen sulfate	$C_{12}H_{22}O_{31}S_7$	886.8
	12943987	[2-[3,4-Disulfonatooxy-2,5-bis(sulfonatooxymethyl)oxolan-2-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate	$C_{12}H_{14}O_{35}S_8^{-8}$	974.8

1 2 3 ... 8 Next >

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

4.2 Parent Compound

[16685690](#)

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

4.3 Related Compounds



Same Parent, Exact	6 Records
Mixtures, Components, and Neutralized Forms	2 Records
Similar Compounds	41 Records

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

4.4 Substances

4.4.1 Related Substances

Same	8 Records
------	-----------

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

4.4.2 Substances by Category

3 Categories Expanded View 

- ▶ Curation Efforts (7)
- ▶ Research And Development (5)
- ▶ Legacy Depositors (1)

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

4.5 Entrez Crosslinks

PubMed	9 Records
Taxonomy	2 Records
Gene	6 Records

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

5 Drug and Medication Information



5.1 Drug Indication



The **sucralfate** suspension [FDA label] and tablet [F4534] are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence [F4519, F4534]. **Sucralfate** is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655, F4519].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

FDA Label

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

5.2 FDA Orange Book



2 items [View More Details](#)

Trade Name	Marketing Status	Application Number	Applicant
CARAFATE	Prescription	N019183	ALLERGAN SALES LLC
CARAFATE	Prescription	N018333	ALLERGAN SALES LLC

▼ from FDA Orange Book

Source: [FDA Orange Book](#)

License Note: Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.

License URL: <https://www.fda.gov/about-fda/about-website/website-policies#linking>

URL: <https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm>

Description: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).

5.3 Drug Labels for Ingredients



Label Information	Total 40 labels
Drug Ingredient	SUCRALFATE
NDC Code(s)	0093-2210-01, 0093-2210-05, 0093-2210-98, 0121-0747-00, 0121-0747-10, 0121-0747-40, 0591-0780-01, 0591-0780-05, 0591-3892-01, 0591-3892-05 ... total 92.
Packagers	A-S Medication Solutions; Actavis Pharma, Inc.; Allergan, Inc.; Aphenia Pharma Solutions - Tennessee, LLC; Atlantic Biologicals Corps; AvKARE, Inc.; Bryant Ranch Prepack; Cardinal Health; Golden State Medical Supply, Inc.; Greenstone LLC; H.J. Harkins Company, Inc.; McKesson Corporation dba SKY Packaging; Medsource Pharmaceuticals; Mylan Institutional Inc.; NCS HealthCare of KY, Inc dba Vanguard Labs ; Northwind Pharmaceuticals, LLC; NuCare Pharmaceuticals, Inc.; Pharmaceutical Associates, Inc.; Physicians Total Care, Inc.; Precision Dose Inc.; Preferred Pharmaceuticals Inc.; REMEDYREPACK INC.; RPK Pharmaceuticals, Inc.; STAT RX USA LLC; State of Florida DOH Central Pharmacy; Teva Pharmaceuticals USA, Inc.; VistaPharm, Inc.

▼ from DailyMed

Source: [DailyMed](#)

Record Name: SUCRALFATE

URL: <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=SUCRALFATE>

Description: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).

6 Pharmacology and Biochemistry



6.1 Pharmacology



This drug aids in the healing of duodenal ulcers, relieving painful inflammation by creating a protective mechanical barrier between the lining or skin of the gastrointestinal tract and damaging substances [A177655]. In addition, **sucralfate** acts to increase levels of growth factors locally, and also causes an increase in prostaglandins which are important in the healing of the mucosa (lining) of the gastrointestinal tract [A177655].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

6.2 MeSH Pharmacological Classification



Anti-Ulcer Agents

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See [all compounds classified as Anti-Ulcer Agents](#).)

▼ from MeSH

Source: [MeSH](#)

Record Name: Anti-Ulcer Agents

URL: <https://www.ncbi.nlm.nih.gov/mesh/68000897>

6.3 Absorption, Distribution and Excretion



Absorption

This drug is absorbed from the gastrointestinal tract in very minimal quantities [FDA label]. The adsorbed sulfated disaccharide is excreted in the urine [F4519]. This drug contains **aluminum** and after the administration of 1 g of **sucralfate** 4 times per day, about 0.001% to 0.017% of this **aluminum** content is absorbed in patients with normal renal function [F4519]. This number is expected to increase in those with impaired renal function [F4519].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

Route of Elimination

The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours [FDA label, F4537].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

Volume of Distribution

This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions [FDA label].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

Clearance

Sucralfate contains **aluminum**. The administration of **sucralfate** in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed **aluminum** may be decreased, causing possible **aluminum** toxicity [F4519]. In dialyzed patients diagnosed with chronic renal failure, **aluminum** toxicity related to **sucralfate** has been observed and reported. The daily amount of **aluminum** ingestion (including **sucralfate**) should be carefully examined before administering **sucralfate** in combination with other drugs also containing **aluminum**, including various antacids [F4519].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

6.4 Metabolism/Metabolites



This drug is absorbed in very small quantities and is not significantly metabolized [FDA label, F4519].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

6.5 Biological Half-Life



The half-life is not known. In animals, the elimination half-life of the **sucrose** component of this drug is from 6-20 h [F4537].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

6.6 Mechanism of Action



The mechanism of action of this drug in the healing duodenal ulcers is not yet completely defined, however, there are several probable mechanisms that adequately describe the healing activity of **sucralfate**. There is evidence that **sucralfate** acts locally to aid in tissue healing, and not systemically [FDA label]. Studies in both humans and animals have indicated that **sucralfate** forms a complex that binds to protein-rich exudate found on the surface of ulcers. It binds to albumin and fibrinogen [A11831, A177685] preventing blood clot lysis by stomach acid (**hydrochloric acid**). **Sucralfate** increases the tissue levels of fibroblast growth factors and epidermal growth factors [A17638, A16741], leading to an increase in prostaglandins at the gastrointestinal tract lining, which promote the healing of gastrointestinal ulcers [A177655]. In the laboratory setting, a **sucralfate**-albumin film provides a barrier against the entry of **hydrogen** ions, which are a component of gastric acid. In humans, **sucralfate**, given at therapeutic doses for ulcers, decreases pepsin activity in gastric fluids by 32% [FDA label]. Pepsin has been shown to be damaging to tissues, further aggravating ulcer lesion inflammation [A177667]. Bile salts have been implicated in mucosal injury to the gastrointestinal tract [A177697, A177700]. **Sucralfate** has also been shown to adsorb bile salts in the laboratory, setting, which could further contribute to its beneficial effects in ulcer healing [FDA label].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

7 Toxicity



7.1 Toxicological Information



7.1.1 Toxicity Summary



****Overdose**** Overdosage has never been observed with [sucralfate](#) [F4519]. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies [F4519]. It is likely that overdose of [sucralfate](#) in humans would result in constipation, and supportive treatment would be advised [F4519]. ****Use in pregnancy**** This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women. Due to the fact that the results of animal studies are not always relevant to human response, [sucralfate](#) should be used during pregnancy only if it is deemed essential for the mother's health [FDA label]. ****Use in nursing**** Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if [sucralfate](#) is administered to a lactating and nursing woman, caution should be observed [FDA label]. ****Carcinogenesis**** 24 month toxicity studies were performed in rodents, and the dose of [sucralfate](#) reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of [sucralfate](#)-related tumors were noted [FDA label].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

7.1.2 Protein Binding



[Sucralfate](#) is bound to plasma proteins, especially albumin and transferrin [F4519].

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

8 Literature



8.1 NLM Curated PubMed Citations



All NLM Curated PubMed Citations

administration and dosage
adverse effects
analysis
blood
chemistry
economics
immunology
metabolism
pharmacokinetics
pharmacology

therapeutic use
toxicity

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

8.2 Depositor Provided PubMed Citations



194 items View More Rows & Details

SORT BY Publication Date ▼

PMID	Publication Date	Title	Journal
22932084	2012-08-01	Gastro-protecting effect of gefarnate on chronic erosive gastritis with dyspeptic symptoms.	Chinese medical journal
22782130	2012-07-01	[Stress lesions in the upper gastrointestinal tract].	Der Anaesthetist
22076933	2012-06-01	Protective effect of Calamintha officinalis Moench leaves against alcohol-induced gastric mucosa injury in rats. Macroscopic, histologic and phytochemical analysis.	Phytotherapy research : PTR
22226535	2012-03-01	Can sucralfate be effective to protect on peritoneal membrane in patients receiving peritoneal dialysis treatment?	Medical hypotheses
21658805	2012-01-01	Topical sucralfate for pain after oral CO2 laser surgery: a prospective, randomized, controlled trial.	American journal of otolaryngology

1 2 3 ... 39 Next >

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

8.3 Synthesis References



Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency [sucralfate](#)." U.S. Patent US4990610, issued March, 1973.

▼ from DrugBank

Source: DrugBank

Record Name: Sucralfate

URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

8.4 General References



1. Rees WD: Mechanisms of gastroduodenal protection by **sucralfate**. Am J Med. 1991 Aug 8;91(2A):58S-63S. [PMID:1715673]
2. Candelli M, Carloni E, Armuzzi A, Cammarota G, Ojetti V, Pignataro G, Santoliquido A, Pola R, Pola E, Gasbarrini G, Gasbarrini A: Role of **sucralfate** in gastrointestinal diseases. Panminerva Med. 2000 Mar;42(1):55-9. [PMID:11019606]
3. Lam SK: Why do ulcers heal with **sucralfate**? Scand J Gastroenterol Suppl. 1990;173:6-16. [PMID:2190306]
4. Bardhan KD, Strugala V, Dettmar PW: Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10. [PMID:22242022]
5. Szabo S: The mode of action of **sucralfate**: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PMID:1957124]
6. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: **Sucralfate**: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PMID:7948825]
7. Terao N, Yoshida N, Nagashima R: **Sucralfate**, a basic **aluminum** salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PMID:6892775]
8. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [PMID:2612985]
9. Gadacz TR, Zuidema GD: Bile acid composition in patients with and without symptoms of postoperative reflux gastritis. Am J Surg. 1978 Jan;135(1):48-52. [PMID:341732]
10. Duane WC, Wiegand DM: Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog. J Clin Invest. 1980 Nov;66(5):1044-9. doi: 10.1172/JCI109932. [PMID:7430343]
11. [FDA approval, Sucralfate suspension](#)
12. [Sucralfate tablet FDA approval](#)

▼ from DrugBank

Source: [DrugBank](#)

Record Name: Sucralfate




URL: <http://www.drugbank.ca/drugs/DB00364>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

8.5 Chemical Co-Occurrences in Literature



Showing 3 of 25 [View More Co-Occurrence and Evidence Data](#)

Chemical	Evidence from <input type="text" value="All Time"/>
 <p>Cimetidine CID 2756</p>	<p>7 articles Download CSV View in PubMed</p> <p>Efficacy of sucralfate and cimetidine in protection of the human gastric mucosa against alcohol injury. PMID 3661609; The American journal of medicine 1987 Sep; 83(3B):31-37 Name matches: cimetidine; tagamet <i>carafate</i></p> <p>[Recurrence of duodenal ulcer after therapy with Sucralfat or cimetidine]. PMID 6546829; Wiener klinische Wochenschrift 1984 Feb; 96(4):153-156 Name matches: cimetidine <i>sucralfat</i></p> <p>Sucralfate--alternative therapy for peptic-ulcer disease. PMID 6764389; Clinical pharmacy 1982 ; 1(4):307-314 (Review Article) Name matches: cimetidine <i>carafate</i></p>
 <p>Ranitidine CID 3001055</p>	<p>3 articles Download CSV View in PubMed</p> <p>Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's. PMID 2887321; Clinical and investigative medicine. Medecine clinique et experimentale 1987 May; 10(3):152-170 (Review Article) Name matches: ranitidine <i>sulcrate</i></p> <p>[Effect of stress ulcer prevention on the incidence of ventilation pneumonia at a pulmologic intensive care unit]. PMID 2608643; Pneumologie (Stuttgart, Germany) 1989 Nov; 43(11):665-668 Name matches: ranitidine <i>sucralfat</i></p> <p>Oesophageal reflux disease. Diagnosis, pathophysiology and treatment with special reference to the role of sucralfate. PMID 3475767; Scandinavian journal of gastroenterology. Supplement 1987 ; 127(?):101-109 Name matches: ranitidine <i>antepsin</i></p>
 <p>Reglan CID 441347</p>	<p>2 articles Download CSV View in PubMed</p> <p>Refractory peptic lesions. Therapeutic strategies for ulcers and reflux esophagitis that resist standard regimens. PMID 8095331; Postgraduate medicine 1993 Mar; 93(4):143 (Review Article) Name matches: reglan <i>carafate</i></p> <p>[Erosive reflux-esophagitis and its treatment]. PMID 2057905; Terapevticheskii arkhiv 1991 ; 63(1):81-84 Name matches: cerucal <i>sucralfat</i></p>

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

8.6 Chemical-Disease Co-Occurrences in Literature



Showing 3 of 25 View More Co-Occurrence and Evidence Data

Disease	Evidence from	All Time
Ulcer	15 articles	Download CSV View in PubMed
	<p>Bile salt binding properties of commonly used gastrointestinal drugs: maalox, carafate, and questran. PMID 3171934; Journal of pharmaceutical sciences 1988 Jun; 77(6):527-530 Name matches: ulcer carafate</p> <p>pH-neutralizing esophageal irrigations as a novel mitigation strategy for button battery injury. PMID 29889306; The Laryngoscope 2019 Jan; 129(1):49-57 Name matches: ulcer carafate</p> <p>Antacid, sucralfate, and prostaglandin E2 effects on the growth and potential for translocation of Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus in an in vitro gastric simulation. PMID 1902478; The Journal of burn care & rehabilitation 1991 ; 12(1):7-12 Name matches: ulceration carafate</p>	
Duodenal Ulcer	10 articles	Download CSV View in PubMed
	<p>[Sucralfate: the agent of choice in the treatment of peptic ulcer?]. PMID 2186496; Terapevticheskii arkhiv 1990 ; 62(2):64-67 Name matches: duodenal ulcer antepsin</p> <p>[Effect of stress ulcer prevention on the incidence of ventilation pneumonia at a pulmologic intensive care unit]. PMID 2608643; Pneumologie (Stuttgart, Germany) 1989 Nov; 43(11):665-668 Name matches: stress ulcer sucralfat</p> <p>[Recurrence of duodenal ulcer after therapy with Sucralfat or cimetidine]. PMID 6546829; Wiener klinische Wochenschrift 1984 Feb; 96(4):153-156 Name matches: duodenal ulcer sucralfat</p>	
Stomach Ulcer	7 articles	Download CSV View in PubMed
	<p>[Sucralfate: the agent of choice in the treatment of peptic ulcer?]. PMID 2186496; Terapevticheskii arkhiv 1990 ; 62(2):64-67 Name matches: gastric ulcer antepsin</p> <p>Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's. PMID 2887321; Clinical and investigative medicine. Medecine clinique et experimentale 1987 May; 10(3):152-170 (Review Article) Name matches: gastric ulcers sulcrate</p> <p>Sucralfate--alternative therapy for peptic-ulcer disease. PMID 6764389; Clinical pharmacy 1982 ; 1(4):307-314 (Review Article) Name matches: gastric ulcers carafate</p>	

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

8.7 Chemical-Gene Co-Occurrences in Literature



Showing 2 of 2

Gene	Evidence from	All Time

Gene	Evidence from All Time
Atpase H⁺/K⁺ Transporting Non-Gastric Alpha2 Subunit	<p>2 articles Download CSV View in PubMed</p> <p>Endoscopic resection using band ligation for esophageal SMT in less than 10 mm. PMID 25780296; World journal of gastroenterology 2015 Mar; 21(10):2982-2987 Name matches: proton pump <i>ulcermin</i></p> <p>Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's. PMID 2887321; Clinical and investigative medicine. Medecine clinique et experimentale 1987 May; 10(3):152-170 (Review Article) Name matches: proton pump <i>sulcrate</i></p>
Atpase Plasma Membrane Ca²⁺ Transporting 1	<p>1 article Download CSV View in PubMed</p> <p>Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's. PMID 2887321; Clinical and investigative medicine. Medecine clinique et experimentale 1987 May; 10(3):152-170 (Review Article) Name matches: atpase <i>sulcrate</i></p>

▼ from PubChem

Source: PubChem

URL: <https://pubchem.ncbi.nlm.nih.gov>

Description: Data deposited in or computed by PubChem

9 Biomolecular Interactions and Pathways



9.1 DrugBank Interactions



Showing 1 of 4 [View More](#)

Target	Pepsin
Action	inhibitor
Interaction References	<ol style="list-style-type: none">1. Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [PMID:1617111]2. Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [PMID:2190304]3. Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [PMID:1978840]

▼ from DrugBank

Source: [DrugBank](#)

URL: <http://www.drugbank.ca/drugs/DB00364#targets>

Description: The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

10 Classification



10.1 Ontologies



10.1.1 MeSH Tree



Showing 1 of 1

Sucralfate

A basic aluminum complex of sulfated sucrose.

LINKED RECORDS

Compounds: 1 Substances: 51 PubMed Abstracts: 1,442

CLASSIFICATION (PARENT NODES)

MeSH Tree > Technology And Food And Beverage > Food And Beverages > Food > Food Ingredients > Food Additives > Flavoring Agents > Sweetening Agents > Sucrose

▼ from MeSH

Source: MeSH

Record Name: MeSH Tree

URL: <http://www.nlm.nih.gov/mesh/meshhome.html>

Description: MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.

10.1.2 WHO ATC Classification System



Showing 1 of 1

A02BX02 - Sucralfate

LINKED RECORDS

Compounds: 13 Substances: 41

CLASSIFICATION (PARENT NODES)

ATC Code > A - Alimentary Tract And Metabolism > A02 - Drugs For Acid Related Disorders > A02B - Drugs For Peptic Ulcer And Gastroesophageal Reflux Disease > A02BX - Other Drugs For Peptic Ulcer And Gastroesophageal Reflux Disease

▼ from WHO ATC

Source: WHO ATC

Record Name: ATC Code

URL: https://www.whooc.no/atc_ddd_index/

Description: In the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.

11 Information Sources



FILTER BY SOURCE

ALL SOURCES

1. DailyMed

SUCRALFATE<https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=SUCRALFATE>

2. DrugBank

<http://www.drugbank.ca/drugs/DB00364#targets>*Sucralfate*<http://www.drugbank.ca/drugs/DB00364>

3. FDA Orange Book

LICENSE

Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.

<https://www.fda.gov/about-fda/about-website/website-policies#linking><https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm>

4. MeSH


Sucralfate<https://www.ncbi.nlm.nih.gov/mesh/68013392>*MeSH Tree*<http://www.nlm.nih.gov/mesh/meshhome.html>*Anti-Ulcer Agents*<https://www.ncbi.nlm.nih.gov/mesh/68000897>

5. PubChem

<https://pubchem.ncbi.nlm.nih.gov>

6. WHO ATC

ATC Codehttps://www.whocc.no/atc_ddd_index/



QUEST DIAGNOSTICS INCORPORATED
CLIENT SERVICE 800.669.6605

SPECIMEN INFORMATION
SPECIMEN: HU111925F
REQUISITION: 0050069

PATIENT INFORMATION
BODIN, JEFFREY T
DOB: 05/22/1997 AGE: 11
GENDER: M

ID: BODIN, JEFFREY
PHONE: 985.845.0969

REPORT STATUS FAX COPY

ORDERING PHYSICIAN
POUW, VICTOR VINCENT

CLIENT INFORMATION
L82333 MT99MT12
CHILDREN'S INT'L MED GROUP
1430 LINDBERG DR
SLIDELL, LA 70458-8056


COLLECTED: 03/06/2009 10:11 CT
RECEIVED: 03/06/2009 10:09 CT
REPORTED: 03/13/2009 06:37 CT

COMMENTS: FASTING

Test Name	In Range	Out of Range	Reference Range	Lab
HELICOBACTER PYLORI ANTIBODIES (IGG, IGA, IGM)				
HELICOBACTER PYLORI ANTIBODY (IGG) H. PYLORI AB IGG		NEGATIVE	Reference Range: NEGATIVE	E2
H. pylori serology testing measures antibodies to H. pylori and is not recommended for the diagnosis of active infection. The American College of Gastroenterology and the American Gastroenterological Association recommend either the urea breath test (test code #14839X) or the fecal antigen test (test code# 34838X) for diagnosis and confirmation of eradication in cases of suspected or proven Helicobacter pylori infection.				
HELICOBACTER PYLORI ANTIBODY (IGA) H. PYLORI AB IGA		NEGATIVE	Reference Range: NEGATIVE	E2
HELICOBACTER PYLORI ANTIBODY (IGM) H. PYLORI AB IGM		NEGATIVE	Reference Range: NEGATIVE	E2
FSH/LH, PEDIATRICS LH, PEDIATRICS	0.86		mIU/mL Reference Range: < OR = 6.64	E2
Male Reference Ranges for LH (Luteinizing Hormone), Pediatric:				
Males:				
3-7 years	< or =	0.26	mIU/mL	
8-9 years	< or =	1.40	mIU/mL	
10-11 years	< or =	6.64	mIU/mL	
12-14 years		0.85-6.87	mIU/mL	
15-17 years		0.90-7.82	mIU/mL	

BODIN, JEFFREY T - HU111925F

Page 1 - Continued on Page 2



PATIENT INFORMATION
BODIN, JEFFREY T

REPORT STATUS FAX COPY

QUEST DIAGNOSTICS INCORPORATED

ORDERING PHYSICIAN
POUW, VICTOR VINCENT

COLLECTED: 03/06/2009 10:11 CT
REPORTED: 03/13/2009 06:37 CT

DOB: 05/22/1997 **AGE:** 11
GENDER: M
ID: BODIN, JEFFREY

Test Name	In Range	Out of Range	Reference Range	Lab
18-20 years	0.95-8.44 mIU/mL			
Tanner Stage				
I	< or = 0.50 mIU/mL			
II	< or = 1.73 mIU/mL			
III	0.09-4.09 mIU/mL			
IV-V	0.18-10.43 mIU/mL			

FSH (FOLLICLE STIMULATING HORMONE), PEDIATRICS
FSH, PEDIATRICS

0.81

mIU/mL

EZ

Reference Range:
EARLY PREPUBERTAL:
 0.30-4.00

Male Pediatric Reference Ranges for FSH:

0-9 years/prepubertal*: <3.00 mIU/mL
 10-13 years/early pubertal: 0.30-4.00 mIU/mL
 14-17 years: 0.40-7.40 mIU/mL

*FSH peaks (typically 3.00-6.00 mIU/mL for this assay) in male infants at 4 months of age, falling to prepubertal levels by 1 year of age. (Forest MG, Ducharme JR, Gonadotropic and gonadal hormones. Ch8, in: Bertrand et al, eds. Pediatric Endocrinology, 2nd Ed. Baltimore: Williams & Wilkins, 1993).

COMPREHENSIVE METABOLIC

RGA

PANEL W/EGFR
GLUCOSE

75

65-99 mg/dL
FASTING REFERENCE INTERVAL
 7-20 mg/dL
 0.50-1.30 mg/dL

UREA NITROGEN (BUN)
CREATININE

13

0.67

PATIENT IS <18 YEARS OLD. UNABLE TO CALCULATE EGFR.
BUN/CREATININE RATIO NOT APPLICABLE
BUN/CREATININE RATIO IS NOT REPORTED WHEN THE BUN AND CREATININE VALUES ARE WITHIN NORMAL LIMITS.

6-22 (calc)

SODIUM

138

135-146 mmol/L

POTASSIUM

3.7

L

3.8-5.1 mmol/L

CHLORIDE


104

98-110 mmol/L

CARBON DIOXIDE

22

21-33 mmol/L



PATIENT INFORMATION
BODIN, JEFFREY T

REPORT STATUS FAX COPY

QUEST DIAGNOSTICS INCORPORATED

ORDERING PHYSICIAN
 POW, VICTOR VINCENT

COLLECTED: 03/06/2009 10:11 CT
 REPORTED: 03/13/2009 06:37 CT

DOB: 05/22/1997 AGE: 11
 GENDER: M
 ID: BODIN, JEFFREY

Test Name	In Range	Out of Range	Reference Range	Lab
CALCIUM	9.7		8.9-10.4 mg/dL	
PROTEIN, TOTAL	7.4		6.3-8.2 g/dL	
ALBUMIN	5.1		3.6-5.1 g/dL	
GLOBULIN	2.3		2.1-3.5 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO		2.2 H	1.0-2.1 (calc)	
BILIRUBIN, TOTAL	0.3		0.2-1.1 mg/dL	
ALKALINE PHOSPHATASE	126		91-476 U/L	
AST	19		12-32 U/L	
ALT	10		8-30 U/L	

IGF-I 122 ng/mL E2
 Reference Range:
 80-723

Pediatric Male Reference Ranges for IGF-I:

1-7 days	< or = 31 ng/mL
8-14 days	< or = 43 ng/mL
15 days-1 year	25-265 ng/mL
1-2 years	45-222 ng/mL
3-4 years	36-202 ng/mL
5-6 years	32-259 ng/mL
7-8 years	65-278 ng/mL
9-10 years	52-330 ng/mL
11-12 years	80-723 ng/mL
13-14 years	142-855 ng/mL
15-16 years	176-845 ng/mL
17-18 years	152-668 ng/mL

**Tanner Stages
 (7-17 years)**

Tanner I	59-296 ng/mL
Tanner II	56-432 ng/mL
Tanner III	135-778 ng/mL
Tanner IV	230-855 ng/mL
Tanner V	181-789 ng/mL

TESTOSTERONE, FREE AND
 TOTAL, LC/MS/MS
 IGF BINDING PROTEIN 3
 (IGFBP 3)

PENDING


3.7 mg/L

E2

Reference Range:
 2.4-8.4

**Pediatric Reference Ranges (mg/L) for IGF
 Binding Protein-3 (IGFBP-3):**

Age Units



PATIENT INFORMATION
BODIN, JEFFREY T

REPORT STATUS FAX COPY

QUEST DIAGNOSTICS INCORPORATED

ORDERING PHYSICIAN
POUW, VICTOR VINCENT

COLLECTED: 03/06/2009 10:11 CT
REPORTED: 03/13/2009 06:37 CT

DOB: 05/22/1997 AGE: 11
GENDER: M
ID: BODIN, JEFFREY

Test Name	In Range	Out of Range	Reference Range	Lab
1-7 days		0.7		
8-15 days		0.5-1.4		
16 days-1 year		0.7-3.6		
2 years		0.8-3.9		
3 years		0.9-4.3		
4 years		1.0-4.7		
5 years		1.1-5.2		
6 years		1.3-5.6		
7 years		1.4-6.1		
8 years		1.6-6.5		
9 years		1.8-7.1		
10 years		2.1-7.7		
11 years		2.4-8.4		
12 years		2.7-8.9		
13 years		3.1-9.5		
14 years		3.3-10.0		
15 years		3.5-10.0		
16 years		3.4-9.5		
17 years		3.2-8.7		

Male Reference Ranges (mg/L) for IGF Binding Protein-3 (IGFBP-3) by Pubertal (Tanner) Stage:

Males

Tanner I	1.4-5.2
Tanner II	2.3-6.3
Tanner III	3.1-8.9
Tanner IV	3.7-8.7
Tanner V	2.6-8.6


T4, FREE	1.3	0.9-1.4 ng/dL	BGA
TSH, 3RD GENERATION	3.84	0.50-4.30 mIU/L	BGA

HARD COPY TO FOLLOW

PATIENT RESULTS CONTAINED IN A FACSIMILE OR ELECTRONIC MEDICAL REPORT ARE PROVIDED ONLY UPON THE REQUEST OF THE PHYSICIAN OR AUTHORIZED PERSON. FACSIMILE OR ELECTRONIC MEDICAL REPORTS THAT ARE CREATED BEFORE FINAL RESULTS ARE REPORTED ARE CONSIDERED TO BE INTERIM RESULTS ONLY AND ARE SUBJECT TO CHANGE BY THE LABORATORY.

BODIN, JEFFREY T - HU111925F

Page 4 - Continued on Page 5



QUEST DIAGNOSTICS INCORPORATED
CLIENT SERVICE 800.669.6605

SPECIMEN INFORMATION
SPECIMEN: HU800247H
REQUISITION: 3645304

PATIENT INFORMATION
BODIN,JEFFERY
DOB: 05/22/1997 AGE: 12
GENDER: M FASTING: U

ID:
PHONE: 504.596.2826

REPORT STATUS FINAL
ORDERING PHYSICIAN
CASEY,SHERRI B

CLIENT INFORMATION
L34857 MT03MT03
CHILDRENS MEDICAL CENTER FAX
71107 HIGHWAY 21
COVINGTON, LA 70433-7151

COLLECTED: 08/24/2009
RECEIVED: 08/24/2009 19:13 CT
REPORTED: 08/27/2009 11:51 CT

Test Name In Range Out of Range Reference Range Lab

CULTURE, CAMPYLOBACTER

NO

MICRO NUMBER: 90437739
TEST STATUS: FINAL
SPECIMEN SOURCE: STOOL
SPECIMEN COMMENTS: ADEQUATE
RESULT: NO ENTERIC CAMPYLOBACTER ISOLATED

CULTURE, SALMONELLA AND SHIGELLA

NO

MICRO NUMBER: 90437740
TEST STATUS: FINAL
SPECIMEN SOURCE: STOOL
SPECIMEN COMMENTS: ADEQUATE
RESULT: NO SALMONELLA OR SHIGELLA ISOLATED


PERFORMING LABORATORY INFORMATION

NO QUEST DIAGNOSTICS-NEW ORLEANS, 4648 I 10 SERVICE RD, METAIRIE, LA 70001
Laboratory Director: CAROL W SARTIN, CLIA: 19D0648716

*called
4m
8/27/09*

BODIN,JEFFERY - HU800247H

Page 1 - End of Report||



QUEST DIAGNOSTICS INCORPORATED
CLIENT SERVICE 800.669.6605

SPECIMEN INFORMATION
SPECIMEN: HU881034H
REQUISITION: 3645300

COLLECTED: 08/25/2009
RECEIVED: 08/26/2009 03:27 CT
REPORTED: 08/26/2009 23:00 CT

PATIENT INFORMATION
BODIN,JEFFREY

DOB: 05/22/1997 AGE: 12
GENDER: M FASTING: U

ID:
PHONE:

REPORT STATUS FINAL

ORDERING PHYSICIAN
CASEY,SHERRI B

CLIENT INFORMATION
L34857 MT03MT03
CHILDRENS MEDICAL CENTER FAX
71107 HIGHWAY 21
COVINGTON, LA 70433-7151

Test Name	In Range	Out of Range	Reference Range	Lab
-----------	----------	--------------	-----------------	-----

=====

OVA AND PARASITES, STOOL CONC AND PERM SMEAR

RGA


MICRO NUMBER: 90442435
TEST STATUS: FINAL
SPECIMEN SOURCE: STOOL
SPECIMEN COMMENTS: ADEQUATE
CONCENTRATION 1: NO OVA OR PARASITES SEEN
TRICHROME 1: NO OVA OR PARASITES SEEN

PERFORMING LABORATORY INFORMATION

RGA QUEST DIAGNOSTICS HOUSTON, 5850 ROGERDALE ROAD, HOUSTON, TX 77072-1602
Laboratory Director: JOHN G BUCK,MD, CLIA: 4500660150

BODIN,JEFFREY - HU881034H

Page 1 - End of Report||



QUEST DIAGNOSTICS INCORPORATED
CLIENT SERVICE 800.669.6605

SPECIMEN INFORMATION
SPECIMEN: HU856251H
REQUISITION: 4080868

COLLECTED: 08/24/2009
RECEIVED: 08/25/2009 02:37 CT
REPORTED: 08/25/2009 23:03 CT

PATIENT INFORMATION
BODIN, JEFFREY

DOB: 05/22/1997 AGE: 12
GENDER: M FASTING: U

ID:
PHONE: 504.596.2826

REPORT STATUS FINAL

ORDERING PHYSICIAN
CASEY, SHERRI B

CLIENT INFORMATION
L34857 MT03M103
CHILDRENS MEDICAL CENTER FAX
71107 HIGHWAY 21
COVINGTON, LA 70433-7151

Test Name	In Range	Out of Range	Reference Range	Lab
-----------	----------	--------------	-----------------	-----

=====

GIARDIA AG, EIA, STOOL

RGA

MICRO NUMBER: 90439558
TEST STATUS: FINAL
SPECIMEN SOURCE: STOOL
SPECIMEN COMMENTS: ADEQUATE
RESULT 1: NOT DETECTED

PERFORMING LABORATORY INFORMATION

RGA QUEST DIAGNOSTICS HOUSTON, 5850 ROGERDALE ROAD, HOUSTON, TX 77072-1602
Laboratory Director: JOHN G BUCK, MD, CLIA: 45D0660150

*Rec 8/24/09
P*

BODIN, JEFFREY - HU856251H

Page 1 - End of Report||


Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics Incorporated. All rights reserved. MH-RPAPR. 7/01

Children's Hospital of New Orleans


Colonoscopy Exam Images

Patient: Jeffrey Bodin
Patient ID: MRN-0445573
Exam Date: 10/15/2009


Attending Physician: Raynorda Brown M.D.
Referring Physician:




perianal area, normal




2]-Normal-anus




3]-Normal-rectum



4]-Normal-rectosigmoid junction




5]-Normal-descending colon




6]-Normal-hepatic flexure




7]-Normal-proximal ascending colon




8]-Normal-ileocecal valve




9]-Normal-cecum



10-Normal-appendiceal orifice




11-Normal-ileocecal valve




12-Normal-terminal ileum



13-Normal-terminal ileum




post biopsy, terminal ileum




post biopsy, terminal ileum




16-Normal-terminal ileum




17-Normal-ileocecal valve




18-Normal-ileocecal valve




19-Normal-mid-ascending colon



20-Normal-proximal ascending colon




21-Normal-hepatic flexure




22-Normal-distal transverse colon




23-Normal-proximal descending colon



24-Normal-mid-sigmoid




25-Normal-rectum



26-erythematous mucosa-colon-rectum

MRN-0445573 Patient Name: Bodin, Jeffrey




Children's Hospital of New Orleans


Esophagogastroduodenoscopy Exam Images

Patient: Jeffrey Bodin
Patient ID: MRN-0445573
Exam Date: 10/15/2009


Attending Physician: Raynorda Brown M.D.
Referring Physician:



1 normal-esophagus-middle third of the esophagus



2 normal-esophagus-distal third of the esophagus




3 erosion-stomach-anterior wall of the antrum



erythematous mucosa-pylorus




5 normal-stomach-cardia




6 erythematous mucosa-stomach-fundus




7 normal-duodenum-2nd portion of the duodenum




8 normal-duodenum-3rd portion of the duodenum



9 post biopsy, duodenum



10 distal bulb



11 erythematous mucosa-pylorus

